Citations

Clear

3485 citation(s) found for "Sy, Sarah".

PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)—Rationale and Design
O’Brien, Sarah H. , Li, Danshi, Mitchell, Lesley , Zee, Pamela, Yee, Donald L., Sung, Lillian , Rodriguez, Vilmarie , Hess, Thomas A. , Newburger, Jane W.

Mayo Clinic

Thrombosis and Haemostasis | March 12, 2019 | Volume: 119 | Issue: 05 | Pages: 844-853

10.1055/s-0039-1679938 | PMID 30861550 Get It

AbstractVenous thromboembolic (VTE) complications in children and adolescents with acute lymphoblastic leukaemia (ALL) and T or B cell lymphoblastic lymphoma (T/B cell LL) can result not only in life-threatening acute complications but also contribute to significant long-term sequelae. The PREVAPIX-ALL study is an open-label randomized controlled study comparing outcomes of treatment with prophylactic dose apixaban versus no anticoagulation (standard of care) in children and adolescents with ALL and T/B cell LL receiving standard induction chemotherapy with asparaginase and the presence of a central venous access device. On day 29 of induction, all patients undergo screening imaging with duplex ultrasonography and echocardiography. The primary efficacy endpoint of the study is a composite of symptomatic and asymptomatic VTE that includes deep vein thrombosis, pulmonary embolism, cerebral sinovenous thrombosis or VTE-related death. The primary safety outcome is major bleeding. Secondary outcomes are central line-associated infections, patency and line replacement, superficial thrombosis, arterial events and death. A planned sample size of 500 randomized paediatric patients enrolled over a period of 5 years is based on the estimation of VTE rates of 20 and 10% in the standard of care and apixaban groups, respectively. An optional biomarker study in 150 patients will examine predictors of increased VTE risk and study in vivo anticoagulant effects of apixaban in children by measuring specific biomarkers in the haemostatic system and inflammatory pathway. This study will provide valuable information for the safety and efficacy of apixaban in VTE prevention during induction in paediatric ALL.
Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Ellis, Paul Anthony, Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Burris, Howard A. , Strasak, Alexander, Patre, Monika, Perez, Edith A. , Toi, Masakazu , Conte, PierFranco , Martín, Miguel , Pieńkowski, Tadeusz , Pivot, Xavier B.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 507-507

10.1200/jco.2015.33.15_suppl.507 Get It

Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
Chanan‐Khan, Asher , Fraser, Graeme , Silva, Rodrigo Santucci, Pylypenko, Halyna, Janssens, Ann , Pristupa, Alexander , Mayer, Jiří , Dilhuydy, Marie‐Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon , Sun, Steven , Mahler, Michelle, Salman, Mariya, Howes, Angela, Cramer, Paula , Demırkan, Fatih , Grosicki, Sebastian , Bartlett, Nancy L. , Hallek, Michael

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA7005-LBA7005

10.1200/jco.2015.33.15_suppl.lba7005 Get It

Increasing adipose burden in young men with metastatic testicular cancer following front-line cytotoxic chemotherapy.
Kato, Caroline, Batra, Kunnal, Mullane, Michael Russell, Lad, Thomas E. , Master, Viraj A. , Arora, Karan , Psutka, Sarah P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 525-525

10.1200/jco.2019.37.7_suppl.525 Get It

525 Background: Exposure to cytotoxic chemotherapy (CC) has been observed to be associated with significant changes in body composition, namely marked lean muscle mass losses, with implications for treatment-related toxicity and oncologic outcomes. However, prior studies predominately include elderly patients who, a priori, are at risk for sarcopenia or severe skeletal muscle deficiency. To date, the impact of CC on body composition in young men with testicular cancer remains undefined. Methods: A retrospective analysis of 19 patients with metastatic testicular cancer treated with CC was performed (2015-17). Lumbar skeletal muscle index (SMI), visceral (VAI), subcutaneous (SCAI), and intramuscular adipose (IMAI) indices (cm2/m2), as well as fat-free mass (FFM, kg) and fat mass (FM, kg) were calculated using cross-sectional soft tissue area measurements on pre- and post-CC computed tomography (CT) axial scans and compared using paired Wilcoxon Signed Rank Tests. Results: Median age was 29 years. According to the NHANES FMI-based classification, 5 (26.3%), 9 (47.4%), 4 (21.1%), and 1 (5.3%) patients had normal, excess, class I, and class II obesity, respectively. Median pre- and post-CC BMI was 27.7 vs. 29.6 kg/m2(p = 0.03). Median pre- and post-CC SMI, VAI, SAI, and IAI were 63.5 vs 57.8 (p = 0.14), 19.9 vs 30.8 (p = 0.01), 47.9 vs 58.2 (p = 0.03), and 3.0 vs 5.2 (p = 0.002), respectively. Median muscle density pre- and post-CC were 47.0 vs 43.6 HU (p = 0.002). Pre- and post-chemotherapy FFM were 21.5 vs 19.5 kg, representing an overall median loss of 2.8%, (IQR -10.1, +4.7; Range -49.5 - +16.3; p = 0.14). Conversely, pre- and post-CC FM were 6.6 vs 7.5 kg, representing an overall median gain of 13.3% (IQR -3.3, +17.0; -24.9 - +50; p = 0.01). Median time between imaging assessments was 121 days. Specific median measures of adiposity each increased significantly, such that VIA increased by 29% (p = 0.01), SCAI increased by 39.7% (p = 0.03), and IMIA increased by 39.7% (p = 0.002). Conclusions: While lean muscularity remained stable, we observed significant increases in total body adipose mass with decreased muscle density in this consecutive case series of testicular cancer patients following CC.
First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.
Patel, Manish R. , Sachdev, Jasgit C. , Hart, Lowell L., Halama, Neils, Ramanathan, Ramesh K., Sarantopoulos, John , Yazji, Salim, Jaeger, Dirk, Adib, Deyaa, Kerschbaumer, Randolf J. , Mahalingam, Devalingam , Liu, Xiaochun , Tsimberidou, Apostolia M.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2518-2518

10.1200/jco.2015.33.15_suppl.2518 Get It

Abstract P361: Body Image Dissatisfaction Influences Cardiovascular Health in Overweight and Obese African American Women
Manjunath, Chandrika , Jenkins, Sarah M. , Breitkopf, Carmen Radecki , Phelan, Sean M. , Hayes, Sharonne N. , Cooper, Lisa A. , Patten, Christi A. , Brewer, LaPrincess C.

Mayo Clinic

Circulation | March 6, 2019 | Volume: 139 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.139.suppl_1.p361 Get It

Introduction: African American women are 5 times less likely than white women to meet at least 5 or more ideal cardiovascular health metrics as defined by the American Heart Association Life’s Simple 7 (LS7) components (smoking, diet, physical activity, BMI, blood pressure, total cholesterol, and glucose). There are few studies probing the influence of sociocultural factors, such as body image dissatisfaction (BID), on these disparities. A better understanding of the impact of BID on cardiovascular health could assist in the design of more effective behavior change interventions for African American women. Hypothesis: We hypothesized that BID would have a negative association with cardiovascular health in overweight and obese African American women. Methods: We enrolled 32 women (mean age 49 years [SD 12.9]), from 5 predominantly African American churches participating in a larger community-based participatory study (FAITH! App Pilot Study) of a mobile health lifestyle intervention among African American women and men. We conducted a cross-sectional analysis of baseline data to evaluate the association between BID and both cardiovascular health and select psychosocial factors (e.g. motivation for healthy eating, diet self-regulation). A LS7 composite score was calculated as a measure of overall cardiovascular health (range 0-14). The Pulvers scale, consisting of images of women across the BMI spectrum, was used to measure perceived current and goal body size (rating of figures, 1-9; underweight to very obese). A BID score was calculated as the difference between perceived current and desired body image (range -8-8; BID < 0 [desire to be heavier], BID > 0 [desire to be thinner], BID = 0 [no dissatisfaction]). The BID score range for our cohort was 0-4. Thus, we categorized BID as no/low BID (BID score 0-1) or high BID (BID score 2-4). Results: Twenty-two percent (7/32) of women were overweight (BMI 25-29.9) and 78% (25/32) were obese (BMI (≥ 30). Forty-four percent (14/32) had no/low BID and 56% (18/32) had high BID. Those with high BID were more likely to be obese as compared to no/low BID (94% (17/18) versus 57% (8/14), p=0.03). Although not statistically significant, the mean LS7 composite score was 1 point higher among those with no/low BID, versus high BID (8.83 versus 7.76, p=0.25). Compared to women with high BID, those with no/low BID were more likely to have greater: intrinsic motivation (P=0.01) and integrated regulation for healthy eating (P=0.007), and self-regulation to reduce fat and caloric intake (P=0.01). Conclusion: Ultimately, although small, our study suggests that African-American women with obesity are more likely to have high BID. High BID was associated with lower motivation and self-regulation, which predict cardiovascular health. BID and other psychosocial factors for behavior change are potential targets for culturally-tailored lifestyle interventions in this group.
Concordance Between Registry and Administrative Data in the Determination of Comorbidity
Etzioni, David A. , Lessow, Cynthia, Bordeianou, Liliana , Kunitake, Hiroko , Deery, Sarah E. , Papageorge, Christina M. , Fuhrman, George M. , Seiler, Rachel L., Ogilvie, James W. , Habermann, Elizabeth B. , Money, Samuel R., Habermann, Elizabeth , Carchman, Evie H. , Chang, Yu‐Hui

Mayo Clinic

Annals of Surgery | March 3, 2019 | Volume: 272 | Issue: 6 | Pages: 1006-1011

10.1097/sla.0000000000003247 | PMID 30817356 Get It

Objective: To characterize agreement between administrative and registry data in the determination of patient-level comorbidities. Background: Previous research finds poor agreement between these 2 types of data in the determination of outcomes. We hypothesized that concordance between administrative and registry data would also be poor. Methods: A cohort of inpatient operations (length of stay 1 day or greater) was obtained from a consortium of 8 hospitals. Within each hospital, National Surgical Quality Improvement Program (NSQIP) data were merged with intra-institutional inpatient administrative data. Twelve different comorbidities (diabetes, hypertension, congestive heart failure, hemodialysis-dependence, cancer diagnosis, chronic obstructive pulmonary disease, ascites, sepsis, smoking, steroid, congestive heart failure, acute renal failure, and dyspnea) were analyzed in terms of agreement between administrative and NSQIP data. Results: Forty-one thousand four hundred thirty-two inpatient surgical hospitalizations were analyzed in this study. Concordance (Cohen Kappa value) between the 2 data sources varied from 0.79 (diabetes) to 0.02 (dyspnea). Hospital variation in concordance (intersite variation) was quantified using a test of homogeneity. This test found significant intersite variation at a level of P < 0.001 for each of the comorbidities except for dialysis (P = 0.07) and acute renal failure (P = 0.19). These findings imply significant differences between hospitals in their generation of comorbidity data. Conclusion: This study finds significant differences in how administrative versus registry data assess patient-level comorbidity. These differences are of concern to patients, payers, and providers, each of which had a stake in the integrity of these data. Standardized definitions of comorbidity and periodic audits are necessary to ensure data accuracy and minimize bias.
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Chumsri, Saranya , Serie, Daniel, Li, Zhuo , Pogue–Geile, Katherine L. , Soyano‐Muller, Aixa E., Mashadi-Hossein, Afshin , Warren, Sarah , Lou, Yanyan , Colón‐Otero, Gerardo , Knutson, Keith L. , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Thompson, E. Aubrey , Serie, Daniel J, Knutson, Keith L.

Mayo Clinic

Clinical Cancer Research | February 26, 2019 | Volume: 25 | Issue: 14 | Pages: 4422-4430

10.1158/1078-0432.ccr-18-2206 | PMID 30808774 Get It

Abstract Purpose: Young age has been shown to be an independent predictor of poor outcome in breast cancer. In HER2-positive breast cancer, the effects of aging remain largely unknown. Experimental Design: A total of 4,547 patients were included [3,132 from North Central Cancer Treatment Group (NCCTG) N9831 and 1,415 from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31]. Pathologic stromal tumor-infiltrating lymphocyte (sTIL) and molecular tumor infiltrating lymphocyte (mTIL) signatures were evaluated. Results: In NCCTG N9831, comparable benefit of trastuzumab was observed in all patients [age ≤ 40; HR, 0.43; 95% confidence interval (CI), 0.28–0.66; P &lt; 0.001; and age &gt; 40; HR, 0.56; 95% CI, 0.45–0.69; P &lt; 0.001]. Similar results were observed in NSABP B-31 (age ≤ 40; HR, 0.45; 95% CI, 0.29–0.68; P &lt; 0.001; and age &gt; 40; HR, 0.42; 95% CI, 0.33–0.54; P &lt; 0.001). Among patients who received chemotherapy alone, younger age was associated with poor outcome in the hormone receptor–positive subset, but not the hormone receptor–negative subset, in both trials. Although there was no association between sTILs and age, a small, but significant increase in mTIL CD45 and some immune subset signatures were observed. Among patients who received chemotherapy alone, patients over 40 years of age with lymphocyte-predominant breast cancer had excellent outcome, with 95% remaining recurrence free at 15 years. Conclusions: Among patients treated with trastuzumab, there was no significant difference in outcome related to age. Our study suggests that trastuzumab can negate the poor prognosis associated with young age.
Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer’s disease
Vöglein, Jonathan , Paumier, Katrina L. , Preische, Oliver, Hassenstab, Jason , Benzinger, Tammie L.S. , Noble, James M. , Berman, Sarah , Graff‐Radford, Neill R. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Salloway, Stephen , Xiong, Chengjie , Cairns, Nigel J., Mori, Hiroshi , Masters, Colin L. , Goate, Alison , Buckles, Virginia, Fox, Nick C. , Chrem, Patricio, Allegri, Ricardo , Ringman, John M. , Höglinger, Günter U. , Steiner, Harald , Dieterich, Marianne , Haass, Christian , Laske, Christoph , Morris, John C. , Bateman, Randall J. , Danek, Adrian , Network, Dominantly Inherited Alzheimer, Höglinger, Günter U , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Jucker, Mathias , McDade, Eric , Ghetti, Bernardino , Xiong, Chengjie , Karch, Celeste M. , Schofield, Peter R. , Rossor, Martin N. , Network, Dominantly Inherited Alzheimer, Goate, Alison M , Allegri, Ricardo , Berman, Sarah , Noble, James M

Mayo Clinic

Brain | February 25, 2019 | Volume: 142 | Issue: 5 | Pages: 1429-1440

10.1093/brain/awz050 | PMID 30897203 Get It

Aβ deposition in the basal ganglia is common in autosomal dominant Alzheimer’s disease. Vöglein et al. report an increased severity of motor symptoms in autosomal dominant versus sporadic disease in advanced disease stages. Motor symptoms are more severe in post-codon 200 presenilin 1 mutation carriers and correlate with basal ganglia Aβ.